Alimera Sciences and pSivida have completed enrolment for the FAME (Fluocinolone Acetonide in diabetic Macular Edema) study of Medidur.
Alimera Sciences and pSivida have completed enrolment for the FAME (Fluocinolone Acetonide in diabetic Macular Edema) study of Medidur.
FAME is a double-masked, randomized, multicentre study that has now enrolled 900 patients across the US, Canada, Europe and India and will assess the safety and efficacy of Medidur for the treatment of diabetic macular oedema (DME).
An independent Data Safety Monitoring Board (DSMB) has recently recommended that the pivotal Phase III clinical trial continue under the current protocol, without change.
Medidur is a tiny, injectable insert that delivers fluocinolone acetonide, a corticosteroid, to the retina for up to three years.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.